ProKidney Corp. (PROK)
2.08
-0.05
(-2.35%)
USD |
NASDAQ |
Mar 18, 16:00
2.08
0.00 (0.00%)
Pre-Market: 08:41
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 294.41M |
| 52 Week High (Daily) | |
| 52 Week Low (Daily) | |
| All-Time High (Daily) | |
| Year to Date Total Returns (Daily) | |
| 1 Month Total Returns (Daily) | |
| 1 Year Total Returns (Daily) | 114.5% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | |
| PS Ratio | 365.37 |
| Price to Book Value | -- |
| EV to EBITDA | |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | |
| Financials | |
| Revenue (5 Year Growth) | |
| Revenue (Quarterly YoY Growth) | |
| EPS Diluted (5 Year Growth) | |
| EPS Diluted (Quarterly YoY Growth) | |
| Debt to Equity Ratio | -0.0042 |
| Return on Equity | |
| Return on Assets | |
| Risk | |
| Beta (5Y) | |
| Max Drawdown (5Y) | -- |
Profile
| ProKidney Corp. is a clinical-stage biotechnology company, which engages in the development of a proprietary cell therapy platform. The firm focuses on the treatment of chronic kidney disease, shifting the emphasis away from management of kidney failure to the restoration of kidney function to stop or delay progression of CKD. It offers REACT, a product candidate that includes selected renal cells prepared from a patient's own, autologous, and renal cells. The company was founded on December 21, 2015 and is headquartered in Winston-Salem, NC. |
| URL | http://www.prokidney.com |
| Investor Relations URL | https://investors.prokidney.com/ |
| HQ State/Province | North Carolina |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | N/A |
| Last Earnings Release | Mar. 18, 2026 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Profile
| ProKidney Corp. is a clinical-stage biotechnology company, which engages in the development of a proprietary cell therapy platform. The firm focuses on the treatment of chronic kidney disease, shifting the emphasis away from management of kidney failure to the restoration of kidney function to stop or delay progression of CKD. It offers REACT, a product candidate that includes selected renal cells prepared from a patient's own, autologous, and renal cells. The company was founded on December 21, 2015 and is headquartered in Winston-Salem, NC. |
| URL | http://www.prokidney.com |
| Investor Relations URL | https://investors.prokidney.com/ |
| HQ State/Province | North Carolina |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | N/A |
| Last Earnings Release | Mar. 18, 2026 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |